AbbVie Launches New Immunology Drugs, Stock Up 31.6% Over Last Year
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 26 2025
0mins
Should l Buy ABBV?
Source: NASDAQ.COM
- New Drug Launch: AbbVie has successfully launched two new immunology drugs, Skyrizi and Rinvoq, which are expected to support revenue growth in the coming years following Humira's loss of exclusivity.
- Market Performance: AbbVie’s stock has risen 31.6% over the past year, significantly outperforming the 19.5% growth of the large-cap pharmaceuticals industry, indicating strong competitive positioning.
- Acquisition Strategy: The company has engaged in a series of acquisitions over the past few years to bolster its early-stage pipeline, aiming for long-term growth despite challenges from Humira's patent expiration.
- Diversified Product Line: AbbVie's oncology and neuroscience drugs are also contributing to revenue growth, further solidifying its position in the pharmaceutical industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 229.480
Low
223.00
Averages
252.00
High
289.00
Current: 229.480
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie Invests $380 Million to Expand Manufacturing in North Chicago
- Major Investment Plan: AbbVie announced a $380 million investment to expand active pharmaceutical ingredient manufacturing in North Chicago over the next decade, aligning with the U.S. government's push for localized production and drug price control.
- New Facility Construction: The project will add two advanced manufacturing facilities focused on producing medicines for neuroscience and metabolic diseases, with construction expected to begin in spring 2026 and operations commencing in 2029, creating hundreds of high-skilled jobs.
- Commitment and Impact: This expansion is part of AbbVie's $100 billion commitment to America, aimed at lowering drug prices and increasing patient access, particularly through offering lower Medicaid prices via TrumpRx.
- Industry Transformation: Amid rapid changes in the pharmaceutical sector, AbbVie's investment not only enhances its manufacturing capabilities in the U.S. but also demonstrates its competitiveness in the global market, especially in the development of obesity and neuroscience medications.
See More
Enveric Biosciences Patent Challenge Withdrawn
- Patent Challenge Withdrawn: Gilgamesh Pharmaceuticals Inc. has withdrawn its Post-Grant Review petition against Enveric Biosciences' U.S. Patent No. 12,138,276, marking a significant victory for Enveric in protecting its intellectual property and ensuring its patent remains unchallenged.
- Legal Response Measures: Enveric hired Fish and Richardson P.C. in October 2025 to contest Gilgamesh's PGR petition and successfully filed a Request for Discretionary Denial, demonstrating the company's proactive stance in safeguarding its intellectual property.
- Importance of Patent Content: Enveric's '276 patent covers
See More
AbbVie: High Dividend Yield and Stable Cash Flow
- Dividend Appeal: AbbVie currently boasts a dividend yield of 2.9%, significantly higher than the S&P 500's 1.1% and the average pharmaceutical company's 1.7%, allowing investors to earn 1.8 percentage points more than the broader market, showcasing its income-generating advantage.
- Cash Flow Stability: While AbbVie's payout ratio exceeds 100%, its cash dividend payout ratio stands at around 60%, indicating a healthy cash flow situation that can sustainably support dividend payments, thereby boosting investor confidence.
- Long-Term Growth Potential: Over the past decade, AbbVie has achieved a remarkable 200% increase in dividends, and although future growth may not match this pace, the company's strong commitment to shareholder returns reflects stability in its dividend policy.
- Diversification Opportunity: AbbVie's aesthetics business provides a stable cash flow foundation; despite Botox losing patent protection, its brand value continues to attract consumers, indicating resilience against industry cycles, making it suitable for dividend investors seeking diversification.
See More
AbbVie: High Dividend Attracts Investors
- Dividend Yield Advantage: AbbVie's current dividend yield stands at 2.9%, which is 1.8 percentage points higher than the S&P 500's 1.1% and 1.2 points above the average pharmaceutical company's 1.7%, showcasing its attractiveness in the market and potential for higher passive income for investors.
- Stable Dividend Growth: Over the past decade, AbbVie has achieved a remarkable 200% increase in dividends, and while future growth may not be as aggressive, the company's commitment to rewarding investors enhances its appeal, particularly for those relying on dividend income.
- Healthy Cash Flow Position: Although AbbVie has a payout ratio exceeding 100%, its cash dividend payout ratio is around 60%, indicating a robust cash flow situation that supports its dividend payments, reassuring investors about sustainability.
- Diversified Investment Portfolio: AbbVie's aesthetics business provides a stable cash flow foundation; despite Botox losing patent protection, its strong brand value suggests that the business may be less affected by typical industry patent cycles, making it suitable for long-term investors seeking diversification.
See More
AbbVie to Invest $380M in New API Plants
- New Plant Construction: AbbVie has announced a $380 million investment to build two new active pharmaceutical ingredient plants at its existing site in North Chicago, Illinois, with full operations expected by 2029, thereby enhancing its production capabilities in neuroscience and obesity treatments.
- Employee Expansion Plan: The opening of these new facilities will create 300 additional jobs for AbbVie, reflecting the company's commitment to not only expanding its production capacity but also contributing to local economic development and job market recovery.
- Ongoing Investment Strategy: This investment follows AbbVie's groundbreaking on another API manufacturing facility in North Chicago in September 2025, demonstrating the company's sustained commitment to drug development and production, aimed at solidifying its leadership position in the biopharmaceutical industry.
- Market Outlook: With the construction of the new plants, AbbVie is set to enhance its competitiveness in the neuroscience and obesity treatment markets, which is expected to provide strong support for the company's future revenue growth and market share expansion.
See More
AbbVie to Invest $380 Million in New Manufacturing Facilities
- Investment Expansion: AbbVie announced a $380 million investment to build two new active pharmaceutical ingredient manufacturing facilities in Illinois, aimed at increasing domestic production capacity for its neuroscience and obesity medications in response to high tariffs on drug imports.
- Construction Timeline: The new facilities are expected to begin construction in spring 2026 and be fully operational by 2029, significantly enhancing AbbVie's production capacity and supply chain stability in the U.S. market.
- Technology Integration: The new facilities will integrate advanced manufacturing technologies and artificial intelligence to support the production of future pipeline medicines, showcasing AbbVie's forward-thinking and innovative capabilities in pharmaceutical manufacturing.
- Job Creation: AbbVie plans to hire 300 employees in North Chicago, including engineers, scientists, manufacturing operators, and lab technicians, which will not only boost the local economy but also enhance the company's competitiveness in the skilled labor market.
See More
AbbVie Invests $380 Million to Expand Manufacturing in North Chicago
- Major Investment Plan: AbbVie announced a $380 million investment to expand active pharmaceutical ingredient manufacturing in North Chicago over the next decade, aligning with the U.S. government's push for localized production and drug price control.
- New Facility Construction: The project will add two advanced manufacturing facilities focused on producing medicines for neuroscience and metabolic diseases, with construction expected to begin in spring 2026 and operations commencing in 2029, creating hundreds of high-skilled jobs.
- Commitment and Impact: This expansion is part of AbbVie's $100 billion commitment to America, aimed at lowering drug prices and increasing patient access, particularly through offering lower Medicaid prices via TrumpRx.
- Industry Transformation: Amid rapid changes in the pharmaceutical sector, AbbVie's investment not only enhances its manufacturing capabilities in the U.S. but also demonstrates its competitiveness in the global market, especially in the development of obesity and neuroscience medications.
See More
Enveric Biosciences Patent Challenge Withdrawn
- Patent Challenge Withdrawn: Gilgamesh Pharmaceuticals Inc. has withdrawn its Post-Grant Review petition against Enveric Biosciences' U.S. Patent No. 12,138,276, marking a significant victory for Enveric in protecting its intellectual property and ensuring its patent remains unchallenged.
- Legal Response Measures: Enveric hired Fish and Richardson P.C. in October 2025 to contest Gilgamesh's PGR petition and successfully filed a Request for Discretionary Denial, demonstrating the company's proactive stance in safeguarding its intellectual property.
- Importance of Patent Content: Enveric's '276 patent covers
See More
AbbVie: High Dividend Yield and Stable Cash Flow
- Dividend Appeal: AbbVie currently boasts a dividend yield of 2.9%, significantly higher than the S&P 500's 1.1% and the average pharmaceutical company's 1.7%, allowing investors to earn 1.8 percentage points more than the broader market, showcasing its income-generating advantage.
- Cash Flow Stability: While AbbVie's payout ratio exceeds 100%, its cash dividend payout ratio stands at around 60%, indicating a healthy cash flow situation that can sustainably support dividend payments, thereby boosting investor confidence.
- Long-Term Growth Potential: Over the past decade, AbbVie has achieved a remarkable 200% increase in dividends, and although future growth may not match this pace, the company's strong commitment to shareholder returns reflects stability in its dividend policy.
- Diversification Opportunity: AbbVie's aesthetics business provides a stable cash flow foundation; despite Botox losing patent protection, its brand value continues to attract consumers, indicating resilience against industry cycles, making it suitable for dividend investors seeking diversification.
See More
AbbVie: High Dividend Attracts Investors
- Dividend Yield Advantage: AbbVie's current dividend yield stands at 2.9%, which is 1.8 percentage points higher than the S&P 500's 1.1% and 1.2 points above the average pharmaceutical company's 1.7%, showcasing its attractiveness in the market and potential for higher passive income for investors.
- Stable Dividend Growth: Over the past decade, AbbVie has achieved a remarkable 200% increase in dividends, and while future growth may not be as aggressive, the company's commitment to rewarding investors enhances its appeal, particularly for those relying on dividend income.
- Healthy Cash Flow Position: Although AbbVie has a payout ratio exceeding 100%, its cash dividend payout ratio is around 60%, indicating a robust cash flow situation that supports its dividend payments, reassuring investors about sustainability.
- Diversified Investment Portfolio: AbbVie's aesthetics business provides a stable cash flow foundation; despite Botox losing patent protection, its strong brand value suggests that the business may be less affected by typical industry patent cycles, making it suitable for long-term investors seeking diversification.
See More
AbbVie to Invest $380M in New API Plants
- New Plant Construction: AbbVie has announced a $380 million investment to build two new active pharmaceutical ingredient plants at its existing site in North Chicago, Illinois, with full operations expected by 2029, thereby enhancing its production capabilities in neuroscience and obesity treatments.
- Employee Expansion Plan: The opening of these new facilities will create 300 additional jobs for AbbVie, reflecting the company's commitment to not only expanding its production capacity but also contributing to local economic development and job market recovery.
- Ongoing Investment Strategy: This investment follows AbbVie's groundbreaking on another API manufacturing facility in North Chicago in September 2025, demonstrating the company's sustained commitment to drug development and production, aimed at solidifying its leadership position in the biopharmaceutical industry.
- Market Outlook: With the construction of the new plants, AbbVie is set to enhance its competitiveness in the neuroscience and obesity treatment markets, which is expected to provide strong support for the company's future revenue growth and market share expansion.
See More
AbbVie to Invest $380 Million in New Manufacturing Facilities
- Investment Expansion: AbbVie announced a $380 million investment to build two new active pharmaceutical ingredient manufacturing facilities in Illinois, aimed at increasing domestic production capacity for its neuroscience and obesity medications in response to high tariffs on drug imports.
- Construction Timeline: The new facilities are expected to begin construction in spring 2026 and be fully operational by 2029, significantly enhancing AbbVie's production capacity and supply chain stability in the U.S. market.
- Technology Integration: The new facilities will integrate advanced manufacturing technologies and artificial intelligence to support the production of future pipeline medicines, showcasing AbbVie's forward-thinking and innovative capabilities in pharmaceutical manufacturing.
- Job Creation: AbbVie plans to hire 300 employees in North Chicago, including engineers, scientists, manufacturing operators, and lab technicians, which will not only boost the local economy but also enhance the company's competitiveness in the skilled labor market.
See More
